U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131644) titled 'Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma' on Aug. 13.
Brief Summary: Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.
Study Start Date: Aug. 13
Study Type: INTERVENTIONAL
Condition:
Kaposiform Hemangioendothelioma
Intervention:
DRUG: Sirolimus
Comparison of different sirolimus discontinuation strategies.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: West China Hospital
Informa...